Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
03.11.2022 - Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January Presentations at upcoming scientific conferences highlight company’s novel approach to treating complement-mediated ...
Source: wallstreet-online.de